Cheng-huang Shen

Jiayi Shi, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Metastatic extramammary Paget's disease successfully treated by trastuzumab deruxtecan: a rare case report.

Metastatic extramammary Paget's disease successfully treated by trastuzumab deruxtecan: a rare case report.

Journal: Frontiers in medicine

Published: March 16, 2026

Distinct molecular signatures of upper tract urothelial carcinoma in Southwestern Taiwan: implications for targeted therapy and disease progression.

Distinct molecular signatures of upper tract urothelial carcinoma in Southwestern Taiwan: implications for targeted therapy and disease progression.

Journal: American journal of cancer research

Published: September 09, 2025

The Influence of Chronic Kidney Disease on the Management of Upper Urinary Tract Cancer Following Radical Nephroureterectomy: A Nationwide Multi-Institutional Study.

The Influence of Chronic Kidney Disease on the Management of Upper Urinary Tract Cancer Following Radical Nephroureterectomy: A Nationwide Multi-Institutional Study.

Journal: Clinical genitourinary cancer

Published: May 01, 2025

Immunosuppression of Tumor-Derived Factors Modulated Neutrophils in Upper Tract Urothelial Carcinoma Through Upregulation of Arginase-1 via ApoA1-STAT3 Axis.

Immunosuppression of Tumor-Derived Factors Modulated Neutrophils in Upper Tract Urothelial Carcinoma Through Upregulation of Arginase-1 via ApoA1-STAT3 Axis.

Journal: Cells

Published: April 07, 2025

Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in vitro and in vivo.

Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in vitro and in vivo.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 12, 2025

Tumor derived adiponectin induces immunosuppressive macrophages in upper tract urothelial carcinoma.

Tumor derived adiponectin induces immunosuppressive macrophages in upper tract urothelial carcinoma.

Journal: Translational oncology

Published: October 09, 2024

Clinical and molecular analysis of JCPyV and BKPyV infection and associated risk of urothelial carcinoma development in the upper tract.

Clinical and molecular analysis of JCPyV and BKPyV infection and associated risk of urothelial carcinoma development in the upper tract.

Journal: Virology journal

Published: August 30, 2024

The potential synergistic effect of combining doxorubicin with vorinostat in urothelial carcinoma therapy.

The potential synergistic effect of combining doxorubicin with vorinostat in urothelial carcinoma therapy.

Journal: Heliyon

Published: August 27, 2024

Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma.

Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma.

Journal: Molecular medicine (Cambridge, Mass.)

Published: July 25, 2024

Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells.

Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells.

Journal: Molecular biology reports

Published: June 13, 2024

Increased Apolipoprotein A1 Expression Correlates with Tumor-Associated Neutrophils and T Lymphocytes in Upper Tract Urothelial Carcinoma.

Increased Apolipoprotein A1 Expression Correlates with Tumor-Associated Neutrophils and T Lymphocytes in Upper Tract Urothelial Carcinoma.

Journal: Current issues in molecular biology

Published: January 31, 2024

Ellagic acid protects against angiotensin II-induced hypertrophic responses through ROS-mediated MAPK pathway in H9c2 cells.

Ellagic acid protects against angiotensin II-induced hypertrophic responses through ROS-mediated MAPK pathway in H9c2 cells.

Journal: Environmental toxicology

Published: October 13, 2023

Showing 1-12 of 67

Last Updated: 09/26/2026